Sıklığı Artan Bir Halk Sağlığı Sorunu: Non-Alkolik Yağlı Karaciğer Hastalığı

Non-alkolik yağlı karaciğer hastalığı (NAYKH), alkol almayan kişiler de alkole bağlı yağlı karaciğer hastalığının histolojik özellikleri ile birlikte olan bir karaciğer hastalığıdır. Tip 2 diabetes mellitus (Tip2 DM), hiperlipidemi ve obezite gibi güncel sorunlarla yakın ilişkisi, Avrupa ve Ortadoğuda %20-30 gibi yüksek bir prevalansa sahip olması, NAYKH üzerine odaklanılmasına yol açmıştır. Basit yağlanmadan (SS) karaciğer hücre yaralanması ve inflamasyonun birlikte olduğu non-alkolik steatohepatit (NASH), ilerlemiş fibrozis ve siroza kadar geniş spektrumlu bir karaciğer hasarını tanımlar. İlerlemiş sirozu olanlarda daha nadir olarak hepatosellüler kanser veya karaciğer yetmezliği gelişebilir. NAYKH tanısı, SS ile NASH ayırımında ve NASH evreleme ve derecelendirmesinde altın standart karaciğer biyopsisidir. Uygun beslenme ve düzenli egzersiz yaparak yavaş ve devamlı kilo kaybının sağlanması hala en etkili tedavi yöntemidir

A Public Health Issue that Increased Prevelance: Non-Acholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD), is a liver disease, that occur in non alcohol users, with same histological features of alcoholic liver disease. The increased importance of NAFLD is depends on its close relation of current problems such as Type 2 Diabetes Mellitus and hyperlipidemia, and its high prevalence as %20-30, in Europe and Middle East. NAFLD has a wide spectrum from simple steatozis (SS), liver cell damage, non alcoholic steatohepatitis (NASH) with inflammation to high stage fibrosis, and cirrhosis. Hepathocellular cancer and liver failure might develop in cirrhosis patients. Biopsy is gold standard for NAFLD diagnosis; differentiate from SS and NASH and defining NASH stages. Nutrition regulations and slow and continuous weight loss with regular exercises is still best treatment method

PDF

___

1Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007; 191: 235-240.
2Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs ina general population: a 5-year observation. Gastroenterology. 2008; 134: 85-94.
3 Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-438.
4Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231.
5 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21: 27-41
6 Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004; 39: 1647-1654.
7 Neuschwander-Tetri BA, Cadwell SH. Nonalcoholic steatohepatitis: Summary of a AASLD single topic conference. Hepatology. 2003; 37: 1202-1219.
8 Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-750.
9 Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22: 1714-1719.
10 Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132: 112-117.
11 Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134: 416-423.
12Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005; 129: 1937-1943.
13 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005; 42: 5-13.
14 Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 7. [Epub ahead of print].
15 Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42: 44-52.
16 Zelber-SagiS, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006; 26: 856-863.
17Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005; 43: 508-514.
18 Ground KE. Liver pathology in aircrew. Aviat Space Environ Med. 1982; 53: 14-18.
19 Minervini MI, Ruppert K, Fontes P, et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol. 2009; 50: 501-510.
20 Browning JD, Szczepaniak LS, Dobbins R,et al. Prevalence of hepatic steatosisin an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-1395.
21 Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005; 41: 372-379.
22 De Ledinghen V, Ratziu V, Causse X, et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases: a prospective multicenter study. J Hepatol. 2006; 45: 592-599.
23 Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008; 49: 600-607.
24 Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008; 47: 1916-1923.
25 Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45: 600-606.
26 Wagenknecht LE, Scherzinger AL, Stamm ER, et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring). 2009; 17: 1240-1246.
27 Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143: 722-728.
28 Wanless IR, Lentz JS. Fatty liver hepatitis (Steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology. 1990; 12: 1106-1110.
29 Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis. Association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000; 26: 98-106.
30 James OF, Day CP. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance. J Hepatol. 1998; 29: 495-501.
31 Fiatarone JR, Coverdale SA, Batery RG, et al. Nonalcoholic steatohepatitis: Impaired antipyrine metabolism and hypertriglyceridaemia may be clues to it is pathogenesis. J Gastroenterol Hepatol. 1991; 6: 585-590.
32Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
33 Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114: 147-152.
34 Day CP, James OFW. Steatohepatitis: a tale of two hits? Gastroenterology. 1998; 114: 842-845.
35 Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129: 113-121.
36Donnelly KL, Smith CI, Schwarzenberg SJ,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115: 1343-1351.
37 Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatosis. Hepatology. 2003; 37: 909-916.
38Letteron P, Sutton A, Mansouri A, et al. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003; 38: 133-140.
39 Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. JAMA. 1999; 282: 1659-1664.
40 Xu A, Wang, Y, Keshaw, H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112: 91-100.
41 Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007; 46: 122-129.
42Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35: 373-379.
43 Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120: 1183-1192.
44 Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204: 521-525.
45 Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003; 285: 906-916.
46 Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007; 133: 496-506.
47 Van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008; 48: 449-457.
48 Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008; 103: 1372-1379.
49 Gören B, Fen T. Non-alkolik yağlı karaciğer hastalığı. Türkiye Klinikleri J Med Sci. 2005; 25: 841-850.
50 Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem. 2007; 40: 776-780.
51 Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 1996; 111: 1645-1653.
52 Chalasani N, Deeg MA, Crabb DW. Systemic lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99: 1497-1502.
53 Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease. J Hepatol. 2002; 37: 56-62.
54 Albano E, Mottaran E, Vidali M, et al. Immune response toward lipid peroxidation products as a predictor of the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Gut. 2005; 54: 987-993.
55 Woodcroft KJ, Hafner MS, Novak RF. Insulin signalling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology. 2002; 35: 263-273.
56 Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P4502E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003; 37: 544-550.
57 Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001; 96: 2448-2455.
58 Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr. 2000; 136: 734-738.
59 Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98: 2485-2490.
60Vigano M, Vergani A, Trombini P, et al. Insulin resistance influences iron metabolism and hepatic steatosis in type 2 diabetes. Gastroenterology. 2000; 118: 986-987.
61 Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999; 31: 421-429.
62George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998; 114: 311-318.
63Woods JR Jr, Plessinger MA, Fantel A. An introduction to reactive oxygen species and their possible roles in substance abuse. Obstet Gynecol Clin North Am. 1998; 25: 219-236.
64Fujita N, Miyachi H, Tanaka H, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev. 2009; 18: 424-432.
65 Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107: 1103-1109.
66 Okanoue T, Yamauchi N, Furutani M, et al. Predictors of nonalcoholic steatohepatitis in Japanese patients: thioredoxin and NASH. In: Okita K, ed. NASH and Nutritional Therapy. Tokyo: Springer. 2005; 64-72.
67 Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic liver disease. J Hepatol. 2003; 38: 32-38.
68 Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30: 1356-1362.
69 Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology. 1999; 30: 847-850.
70 Muse ED, Obici S, Bhanot S, et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest. 2004; 114: 232-239.
71 Asilmaz E, Cohen P, Miyazaki M, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest. 2004; 113: 414-424.
72 Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. Therole of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut. 2001; 48 :206-211.
73 Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003; 37: 1286-1292.
74 Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence ofhepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288: 462-468.
75 Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003; 15: 539-543.
76 Neuschwander-Tetri BA. Nonalcoholic steato-hepatitis and the metabolic syndrome. Am J Med Sci. 2005; 330: 326-335.
77 Marchesini G, Marzocchi R, Agostini F, et al. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16: 421-427.
78 Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865-873.
79 Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007; 91: 1125-1149.
80 Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: Fat or fiction? Am J Gastroenterol. 2001; 96: 274-276.
81 Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-1090.
82 Magalotti D, Marchesini G, Ramilli S, et al. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis. 2004; 36: 406-411.
83 Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004; 19: 537-544.
84 Roberts EA. Steatohepatitis in children. Best Pract Clin Gastroenterol. 2002; 16: 749-765.
85 Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006; 131: 934-945.
86 Kiyici M, Gulten M, Gurel S, etal. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003; 17: 713-718.
87 Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004; 174: 193-196.
88 Gung G, Viola L, Thome M, et al. Ursodeoxycholic acid in the threatment on nonalcoholic steatohepatitis results of a prospective clinical controlled trial. Hepatology. 1997: 326-387.
89 Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116: 1413-1419.
90 Nitecki J, Jackson FW, Alton M, et al. Effect of phlebotomy on non-alcoholic steatohepatitis. Gastroenterology. 2000; 188: A147.
91 Guillygomarc'h A, Mendler MH, Moirand R, et al. Venesection therapy of insulin resistance associated hepatic iron overload. J Hepatol. 2001; 35: 344-349.
92 Ong J, Younossi ZM. Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. Am J Gastroenterol. 2010; 105: 621-623.